Ardelyx, Inc. (ARDX) 10-Year Financial Performance & Capital Metrics

ARDX • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

AboutArdelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Show more

Revenue $334M +168.1%
EBITDA -$26M +58.2%
Net Income -$39M +40.8%
EPS (Diluted) -0.17 +43.3%
Gross Margin 84.85% -1.0%
EBITDA Margin -7.76% +84.4%
Operating Margin -8.38% +83.5%
Net Margin -11.73% +77.9%
ROE -23.01% +53.8%
ROIC -9.05% +77.1%
Debt/Equity 0.89 +163.8%
Interest Coverage -1.39 +80.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 85 (top 15%)
✓Strong 5Y sales CAGR of 129.1%

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y26.57%

5Y129.14%

3Y220.89%

TTM58.12%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM22.09%

EPS CAGR

10Y-

5Y-

3Y-

TTM22.73%

ROCE

10Y Avg-50.46%

5Y Avg-51.86%

3Y Avg-33.62%

Latest-9.24%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.71B	5.58	57.41	43.5%	9.32%		1.92%
CORTCorcept Therapeutics Incorporated	3.72B	35.39	28.77	39.94%	14.19%	16.65%	5.26%	0.01
GUTSFractyl Health, Inc. Common Stock	302.14M	1.97	-1.22	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	465.15M	1.28	-2.03	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	260.56M	2.81	-2.87			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	172.89M	2.03	-3.03	-100%		-282.97%		4.17
ALTAltimmune, Inc.	442.41M	4.24	-3.16	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	771.24M	21.51	-3.24		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	24.03M	24.03M	42M	2.61M	5.28M	7.57M	10.1M	52.16M	124.46M	333.62M
Revenue Growth %	-0.24%	0%	0.75%	-0.94%	1.03%	0.43%	0.33%	4.17%	1.39%	1.68%
Cost of Goods Sold+	829K	1.29M	8.4M	466K	600K	145K	1M	4.12M	17.8M	50.56M
COGS % of Revenue	0.03%	0.05%	0.2%	0.18%	0.11%	0.02%	0.1%	0.08%	0.14%	0.15%
Gross Profit+	23.2M	22.73M	33.6M	2.14M	4.68M	7.43M	9.1M	48.04M	106.66M	283.06M
Gross Margin %	0.97%	0.95%	0.8%	0.82%	0.89%	0.98%	0.9%	0.92%	0.86%	0.85%
Gross Profit Growth %	3.05%	-0.02%	0.48%	-0.94%	1.19%	0.59%	0.23%	4.28%	1.22%	1.65%
Operating Expenses+	53.41M	112.89M	98.72M	93.09M	95.94M	98.21M	163.44M	111.8M	169.94M	311.01M
OpEx % of Revenue	2.22%	4.7%	2.35%	35.71%	18.17%	12.97%	16.19%	2.14%	1.37%	0.93%
Selling, General & Admin	13.53M	18.73M	23.23M	23.71M	24.27M	33.15M	72.3M	76.6M	134.4M	258.69M
SG&A % of Revenue	0.56%	0.78%	0.55%	9.1%	4.6%	4.38%	7.16%	1.47%	1.08%	0.78%
Research & Development	39.88M	94.16M	75.48M	69.37M	71.68M	65.05M	91.14M	35.2M	35.54M	52.32M
R&D % of Revenue	1.66%	3.92%	1.8%	26.61%	13.57%	8.59%	9.03%	0.67%	0.29%	0.16%
Other Operating Expenses	-261K	508K	0	0	0	0	0	0	0	0
Operating Income+	-29.39M	-112.89M	-65.11M	-90.95M	-91.26M	-90.78M	-154.35M	-63.76M	-63.28M	-27.95M
Operating Margin %	-1.22%	-4.7%	-1.55%	-34.89%	-17.28%	-11.99%	-15.29%	-1.22%	-0.51%	-0.08%
Operating Income Growth %	-17.79%	-2.84%	0.42%	-0.4%	-0%	0.01%	-0.7%	0.59%	0.01%	0.56%
EBITDA+	-28.56M	-111.6M	-62.48M	-88.27M	-86.92M	-86.81M	-151.54M	-62.62M	-61.98M	-25.89M
EBITDA Margin %	-1.19%	-4.64%	-1.49%	-33.86%	-16.46%	-11.47%	-15.01%	-1.2%	-0.5%	-0.08%
EBITDA Growth %	-21.63%	-2.91%	0.44%	-0.41%	0.02%	0%	-0.75%	0.59%	0.01%	0.58%
D&A (Non-Cash Add-back)	829K	1.29M	2.64M	2.68M	4.34M	3.97M	2.81M	1.14M	1.29M	2.06M
EBIT	-29.39M	-112.89M	-63.16M	-87.76M	-88.91M	-89.21M	-153.66M	-62.13M	-56.65M	-18.78M
Net Interest Income+	0	0	0	-3.53M	-5.73M	-5.1M	-4.5M	-5.07M	-8.87M	-20.09M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	0	0	0	3.53M	5.73M	5.1M	4.5M	5.07M	8.87M	20.09M
Other Income/Expense	-261K	508K	1.96M	-347K	-3.37M	-3.53M	-3.81M	-3.44M	-2.24M	-10.92M
Pretax Income+	-29.65M	-112.39M	-63.16M	-91.29M	-94.64M	-94.31M	-158.16M	-67.2M	-65.52M	-38.87M
Pretax Margin %	-1.23%	-4.68%	-1.5%	-35.02%	-17.92%	-12.46%	-15.66%	-1.29%	-0.53%	-0.12%
Income Tax+	-29K	29K	1.18M	4K	303K	2K	4K	8K	547K	266K
Effective Tax Rate %	1%	1%	1.02%	1%	1%	1%	1%	1%	1.01%	1.01%
Net Income+	-29.62M	-112.39M	-64.34M	-91.3M	-94.94M	-94.31M	-158.16M	-67.21M	-66.07M	-39.14M
Net Margin %	-1.23%	-4.68%	-1.53%	-35.02%	-17.98%	-12.46%	-15.66%	-1.29%	-0.53%	-0.12%
Net Income Growth %	-8.22%	-2.79%	0.43%	-0.42%	-0.04%	0.01%	-0.68%	0.58%	0.02%	0.41%
Net Income (Continuing)	-29.62M	-112.39M	-64.34M	-91.3M	-94.94M	-94.31M	-158.16M	-67.21M	-66.07M	-39.14M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.29	-2.80	-1.36	-1.62	-1.47	-1.05	-1.52	-0.42	-0.30	-0.17
EPS Growth %	-6.59%	-1.17%	0.51%	-0.19%	0.09%	0.29%	-0.45%	0.72%	0.29%	0.43%
EPS (Basic)	-1.29	-2.80	-1.36	-1.62	-1.47	-1.05	-1.52	-0.42	-0.30	-0.17
Diluted Shares Outstanding	22.89M	40.12M	47.44M	56.22M	64.48M	89.58M	104.21M	158.69M	219.33M	235.23M
Basic Shares Outstanding	22.89M	40.12M	47.44M	56.22M	64.48M	89.58M	104.21M	158.69M	219.33M	235.23M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	112.23M	203.99M	149.87M	177.72M	252.38M	195.24M	133.65M	153.6M	246.11M	356.45M
Cash & Short-Term Investments	107M	200.82M	133.98M	168.09M	247.51M	186.48M	116.69M	123.91M	184.3M	250.1M
Cash Only	107M	74.6M	75.38M	78.77M	181.13M	91.03M	72.43M	96.14M	21.47M	64.93M
Short-Term Investments	0	126.22M	58.59M	89.32M	66.38M	95.45M	44.26M	27.77M	162.83M	185.17M
Accounts Receivable	0	0	10.8M	5.08M	750K	0	502K	7.73M	22.03M	57.7M
Days Sales Outstanding	-	-	93.82	711.94	51.84	-	18.15	54.12	64.61	63.13
Inventory	0	0	0	0	0	0	0	3.28M	12.45M	21.17M
Days Inventory Outstanding	-	-	-	-	-	-	-	290.97	255.33	152.86
Other Current Assets	0	3.17M	0	0	0	0	1	5.11M	8.41M	11.1M
Total Non-Current Assets+	4.71M	9.14M	8.03M	5.61M	7.41M	6.32M	16.26M	36.46M	51.47M	79.3M
Property, Plant & Equipment	4.71M	8.99M	8.03M	5.61M	7.41M	4.21M	15.11M	10.52M	6.6M	3.88M
Fixed Asset Turnover	5.10x	2.67x	5.23x	0.46x	0.71x	1.80x	0.67x	4.96x	18.86x	86.09x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	100K	0	0	0	0	2.11M	0	0	0	0
Other Non-Current Assets	-100K	148K	0	0	0	0	1.15M	25.95M	44.87M	75.43M
Total Assets+	116.95M	213.13M	157.9M	183.33M	259.78M	201.56M	149.91M	190.07M	297.58M	435.75M
Asset Turnover	0.21x	0.11x	0.27x	0.01x	0.02x	0.04x	0.07x	0.27x	0.42x	0.77x
Asset Growth %	0.03%	0.82%	-0.26%	0.16%	0.42%	-0.22%	-0.26%	0.27%	0.57%	0.46%
Total Current Liabilities+	7.72M	19.2M	17.87M	17.73M	22.22M	28.42M	52.82M	65.6M	50.39M	77.83M
Accounts Payable	2.78M	5.63M	3.93M	1.15M	2.19M	5.63M	4.28M	10.86M	11.14M	16M
Days Payables Outstanding	1.22K	1.59K	170.9	899.18	1.33K	14.16K	1.56K	962.72	228.46	115.52
Short-Term Debt	0	0	0	0	3.79M	6.28M	32.26M	26.71M	0	0
Deferred Revenue (Current)	0	0	0	1000K	1000K	1000K	0	1000K	1000K	1000K
Other Current Liabilities	2.58M	10.4M	10.71M	12.86M	4.64M	5.22M	1.24M	10.09M	15.04M	49.58M
Current Ratio	14.53x	10.62x	8.39x	10.02x	11.36x	6.87x	2.53x	2.34x	4.88x	4.58x
Quick Ratio	14.53x	10.62x	8.39x	10.02x	11.36x	6.87x	2.53x	2.29x	4.64x	4.31x
Cash Conversion Cycle	-	-	-	-	-	-	-	-617.64	91.48	100.48
Total Non-Current Liabilities+	322K	779K	720K	49.79M	50.91M	47.03M	14.47M	26.13M	80.37M	184.63M
Long-Term Debt	0	0	0	49.21M	48.83M	46.62M	0	0	49.82M	150.85M
Capital Lease Obligations	0	0	0	0	2.08M	413K	9.75M	5.86M	1.73M	1.02M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	322K	779K	720K	582K	0	0	4.73M	11.25M	20.18M	25.53M
Total Liabilities	8.04M	19.98M	18.59M	67.52M	73.13M	75.45M	67.3M	91.74M	130.76M	262.46M
Total Debt+	0	0	0	49.21M	57.31M	55.44M	45.5M	36.46M	55.98M	153.44M
Net Debt	-107M	-74.6M	-75.38M	-29.56M	-123.83M	-35.6M	-26.92M	-59.68M	34.51M	88.51M
Debt / Equity	-	-	-	0.42x	0.31x	0.44x	0.55x	0.37x	0.34x	0.89x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-25.73x	-15.94x	-17.80x	-34.28x	-12.57x	-7.13x	-1.39x
Total Equity+	108.9M	193.15M	139.31M	115.81M	186.66M	126.11M	82.62M	98.33M	166.82M	173.29M
Equity Growth %	0.79%	0.77%	-0.28%	-0.17%	0.61%	-0.32%	-0.34%	0.19%	0.7%	0.04%
Book Value per Share	4.76	4.81	2.94	2.06	2.89	1.41	0.79	0.62	0.76	0.74
Total Shareholders' Equity	108.9M	193.15M	139.31M	115.81M	186.66M	126.11M	82.62M	98.33M	166.82M	173.29M
Common Stock	3K	5K	5K	6K	9K	9K	13K	20K	23K	24K
Retained Earnings	-101.49M	-213.88M	-278.21M	-365.51M	-460.45M	-554.76M	-712.93M	-780.14M	-846.2M	-885.34M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-3.81M	-71K	-47K	-38K	20K	-4K	-6K	-54K	224K	57K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-71.84M	-92.53M	-65.19M	-70.27M	-76.48M	-81.44M	-152.55M	-70.04M	-89.72M	-44.81M
Operating CF Margin %	-2.99%	-3.85%	-1.55%	-26.96%	-14.48%	-10.76%	-15.11%	-1.34%	-0.72%	-0.13%
Operating CF Growth %	-6.36%	-0.29%	0.3%	-0.08%	-0.09%	-0.06%	-0.87%	0.54%	-0.28%	0.5%
Net Income	-29.62M	-112.39M	-64.34M	-91.3M	-94.94M	-94.31M	-158.16M	-67.21M	-66.07M	-39.14M
Depreciation & Amortization	829K	1.29M	2.64M	2.68M	2.5M	1.82M	1.44M	1.14M	1.29M	2.06M
Stock-Based Compensation	2.63M	5.32M	9.59M	9.23M	9.94M	10.58M	12.04M	10.75M	13.53M	37.38M
Deferred Taxes	65K	-86K	11K	-1.02M	-262K	315K	-190K	0	0	0
Other Non-Cash Items	458K	540K	567K	792K	3.3M	3.37M	4.25M	4.84M	4.91M	4.05M
Working Capital Changes	-46.2M	12.79M	-13.66M	9.35M	2.98M	-3.21M	-11.92M	-19.57M	-43.39M	-49.17M
Change in Receivables	2.58M	0	-10.8M	10.71M	85K	750K	-502K	-7.23M	-14.3M	-35.67M
Change in Inventory	-2.08M	0	-1.9M	1.88M	-3.41M	-750K	-10.37M	-28.35M	-21.14M	-41.7M
Change in Payables	-371K	2.15M	-1.03M	-2.73M	39K	3.44M	-1.35M	6.58M	279K	4.86M
Cash from Investing+	-3.45M	-131.08M	65.29M	-29.89M	23.37M	-31.44M	50.95M	18.41M	-131.25M	-18.32M
Capital Expenditures	-3.45M	-4.87M	-2.35M	-311K	-325K	-324K	-1.87M	-55K	-344K	-1.01M
CapEx % of Revenue	0.14%	0.2%	0.06%	0.12%	0.06%	0.04%	0.18%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-126.21M	67.64M	-29.58M	23.7M	-31.44M	52.81M	1.8M	0	0
Cash from Financing+	75.01M	191.2M	685K	103.55M	155.48M	22.78M	83M	75.34M	146.29M	106.59M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	689K	631K	685K	491K	574K	1.85M	1.3M	9.78M	4.67M	-1M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-75.29M	-97.4M	-67.55M	-70.58M	-76.81M	-81.76M	-154.42M	-70.1M	-90.06M	-45.82M
FCF Margin %	-3.13%	-4.05%	-1.61%	-27.08%	-14.54%	-10.8%	-15.29%	-1.34%	-0.72%	-0.14%
FCF Growth %	-7.52%	-0.29%	0.31%	-0.05%	-0.09%	-0.06%	-0.89%	0.55%	-0.28%	0.49%
FCF per Share	-3.29	-2.43	-1.42	-1.26	-1.19	-0.91	-1.48	-0.44	-0.41	-0.19
FCF Conversion (FCF/Net Income)	2.43x	0.82x	1.01x	0.77x	0.81x	0.86x	0.96x	1.04x	1.36x	1.14x
Interest Paid	0	0	0	0	4.92M	4.2M	3.47M	2.9M	4.24M	11.41M
Taxes Paid	69K	0	3K	4K	2K	1K	4K	6K	51K	266K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-34.93%	-74.42%	-38.7%	-71.57%	-62.78%	-60.31%	-151.55%	-74.28%	-49.83%	-23.01%
Return on Invested Capital (ROIC)	-1161.93%	-140.59%	-53.52%	-90.84%	-91.83%	-88.8%	-158.35%	-101.37%	-39.55%	-9.05%
Gross Margin	96.55%	94.61%	80%	82.13%	88.64%	98.08%	90.1%	92.11%	85.7%	84.85%
Net Margin	-123.29%	-467.77%	-153.19%	-3502.03%	-1797.77%	-1245.71%	-1566.46%	-128.85%	-53.08%	-11.73%
Debt / Equity	-	-	-	0.42x	0.31x	0.44x	0.55x	0.37x	0.34x	0.89x
Interest Coverage	-	-	-	-25.73x	-15.94x	-17.80x	-34.28x	-12.57x	-7.13x	-1.39x
FCF Conversion	2.43x	0.82x	1.01x	0.77x	0.81x	0.86x	0.96x	1.04x	1.36x	1.14x
Revenue Growth	-24.02%	0%	74.81%	-93.79%	102.57%	43.36%	33.36%	416.57%	138.61%	168.06%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	300K	1.4M	-	15.6M	82.53M	319.2M
Product Growth	-	-	-	366.67%	-	-	429.01%	286.78%
Product, IBSRELA	-	-	-	-	-	-	80.06M	158.29M
Product, IBSRELA Growth	-	-	-	-	-	-	-	97.70%
License	-	2.32M	-	706K	5.01M	35.03M	35.81M	78K
License Growth	-	-	-	-	610.06%	598.80%	2.22%	-99.78%
Collaborative Development	-	-	-	-	4.18M	-	-	-
Collaborative Development Growth	-	-	-	-	-	-	-	-
Other Product Or Services Revenue	-	287K	322K	-	-	-	-	-
Other Product Or Services Revenue Growth	-	-	12.20%	-	-	-	-	-

Revenue by Geography

	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	15.6M	83.28M	319.2M
UNITED STATES Growth	-	-	-	-	-	-	433.82%	283.30%
North America	-	2.32M	-	806K	-	-	59K	14.34M
North America Growth	-	-	-	-	-	-	-	24206.78%
Asia Pacific	42M	287K	5.28M	6.76M	10.08M	36.53M	41.12M	78K
Asia Pacific Growth	-	-99.32%	1740.07%	28.10%	49.06%	262.23%	12.58%	-99.81%
CANADA	-	-	-	-	13K	31K	-	-
CANADA Growth	-	-	-	-	-	138.46%	-	-

Frequently Asked Questions

Growth & Financials

Ardelyx, Inc. (ARDX) reported $398.2M in revenue for fiscal year 2024. This represents a 7261% increase from $5.4M in 2012.

Ardelyx, Inc. (ARDX) grew revenue by 168.1% over the past year. This is strong growth.

Ardelyx, Inc. (ARDX) reported a net loss of $56.5M for fiscal year 2024.

Dividend & Returns

Ardelyx, Inc. (ARDX) has a return on equity (ROE) of -23.0%. Negative ROE indicates the company is unprofitable.

Ardelyx, Inc. (ARDX) had negative free cash flow of $55.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Ardelyx, Inc. (ARDX) 10-Year Financial Performance & Capital Metrics

ARDX • • Industrial / General

HealthcareBiotechnologyMetabolic & Liver DiseasesObesity & Metabolic Disorders

Revenue $334M +168.1%
EBITDA -$26M +58.2%
Net Income -$39M +40.8%
EPS (Diluted) -0.17 +43.3%
Gross Margin 84.85% -1.0%
EBITDA Margin -7.76% +84.4%
Operating Margin -8.38% +83.5%
Net Margin -11.73% +77.9%
ROE -23.01% +53.8%
ROIC -9.05% +77.1%
Debt/Equity 0.89 +163.8%
Interest Coverage -1.39 +80.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 85 (top 15%)
✓Strong 5Y sales CAGR of 129.1%

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y26.57%

5Y129.14%

3Y220.89%

TTM58.12%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM22.09%

EPS CAGR

10Y-

5Y-

3Y-

TTM22.73%

ROCE

10Y Avg-50.46%

5Y Avg-51.86%

3Y Avg-33.62%

Latest-9.24%

Peer Comparison

Obesity & Metabolic Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
MNKDMannKind Corporation	1.71B	5.58	57.41	43.5%	9.32%		1.92%
CORTCorcept Therapeutics Incorporated	3.72B	35.39	28.77	39.94%	14.19%	16.65%	5.26%	0.01
GUTSFractyl Health, Inc. Common Stock	302.14M	1.97	-1.22	-22.5%	-40732.33%	-241.68%		2.20
LXRXLexicon Pharmaceuticals, Inc.	465.15M	1.28	-2.03	24.81%	-96.77%	-57.07%		0.74
RZLTRezolute, Inc.	260.56M	2.81	-2.87			-52.45%		0.01
MISTMilestone Pharmaceuticals Inc.	172.89M	2.03	-3.03	-100%		-282.97%		4.17
ALTAltimmune, Inc.	442.41M	4.24	-3.16	-95.31%	-4195.75%	-45.21%		0.01
BIOABioAge Labs, Inc.	771.24M	21.51	-3.24		-12.81%	-27.32%		0.03

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	24.03M	24.03M	42M	2.61M	5.28M	7.57M	10.1M	52.16M	124.46M	333.62M
Revenue Growth %	-0.24%	0%	0.75%	-0.94%	1.03%	0.43%	0.33%	4.17%	1.39%	1.68%
Cost of Goods Sold+	829K	1.29M	8.4M	466K	600K	145K	1M	4.12M	17.8M	50.56M
COGS % of Revenue	0.03%	0.05%	0.2%	0.18%	0.11%	0.02%	0.1%	0.08%	0.14%	0.15%
Gross Profit+	23.2M	22.73M	33.6M	2.14M	4.68M	7.43M	9.1M	48.04M	106.66M	283.06M
Gross Margin %	0.97%	0.95%	0.8%	0.82%	0.89%	0.98%	0.9%	0.92%	0.86%	0.85%
Gross Profit Growth %	3.05%	-0.02%	0.48%	-0.94%	1.19%	0.59%	0.23%	4.28%	1.22%	1.65%
Operating Expenses+	53.41M	112.89M	98.72M	93.09M	95.94M	98.21M	163.44M	111.8M	169.94M	311.01M
OpEx % of Revenue	2.22%	4.7%	2.35%	35.71%	18.17%	12.97%	16.19%	2.14%	1.37%	0.93%
Selling, General & Admin	13.53M	18.73M	23.23M	23.71M	24.27M	33.15M	72.3M	76.6M	134.4M	258.69M
SG&A % of Revenue	0.56%	0.78%	0.55%	9.1%	4.6%	4.38%	7.16%	1.47%	1.08%	0.78%
Research & Development	39.88M	94.16M	75.48M	69.37M	71.68M	65.05M	91.14M	35.2M	35.54M	52.32M
R&D % of Revenue	1.66%	3.92%	1.8%	26.61%	13.57%	8.59%	9.03%	0.67%	0.29%	0.16%
Other Operating Expenses	-261K	508K	0	0	0	0	0	0	0	0
Operating Income+	-29.39M	-112.89M	-65.11M	-90.95M	-91.26M	-90.78M	-154.35M	-63.76M	-63.28M	-27.95M
Operating Margin %	-1.22%	-4.7%	-1.55%	-34.89%	-17.28%	-11.99%	-15.29%	-1.22%	-0.51%	-0.08%
Operating Income Growth %	-17.79%	-2.84%	0.42%	-0.4%	-0%	0.01%	-0.7%	0.59%	0.01%	0.56%
EBITDA+	-28.56M	-111.6M	-62.48M	-88.27M	-86.92M	-86.81M	-151.54M	-62.62M	-61.98M	-25.89M
EBITDA Margin %	-1.19%	-4.64%	-1.49%	-33.86%	-16.46%	-11.47%	-15.01%	-1.2%	-0.5%	-0.08%
EBITDA Growth %	-21.63%	-2.91%	0.44%	-0.41%	0.02%	0%	-0.75%	0.59%	0.01%	0.58%
D&A (Non-Cash Add-back)	829K	1.29M	2.64M	2.68M	4.34M	3.97M	2.81M	1.14M	1.29M	2.06M
EBIT	-29.39M	-112.89M	-63.16M	-87.76M	-88.91M	-89.21M	-153.66M	-62.13M	-56.65M	-18.78M
Net Interest Income+	0	0	0	-3.53M	-5.73M	-5.1M	-4.5M	-5.07M	-8.87M	-20.09M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	0	0	0	3.53M	5.73M	5.1M	4.5M	5.07M	8.87M	20.09M
Other Income/Expense	-261K	508K	1.96M	-347K	-3.37M	-3.53M	-3.81M	-3.44M	-2.24M	-10.92M
Pretax Income+	-29.65M	-112.39M	-63.16M	-91.29M	-94.64M	-94.31M	-158.16M	-67.2M	-65.52M	-38.87M
Pretax Margin %	-1.23%	-4.68%	-1.5%	-35.02%	-17.92%	-12.46%	-15.66%	-1.29%	-0.53%	-0.12%
Income Tax+	-29K	29K	1.18M	4K	303K	2K	4K	8K	547K	266K
Effective Tax Rate %	1%	1%	1.02%	1%	1%	1%	1%	1%	1.01%	1.01%
Net Income+	-29.62M	-112.39M	-64.34M	-91.3M	-94.94M	-94.31M	-158.16M	-67.21M	-66.07M	-39.14M
Net Margin %	-1.23%	-4.68%	-1.53%	-35.02%	-17.98%	-12.46%	-15.66%	-1.29%	-0.53%	-0.12%
Net Income Growth %	-8.22%	-2.79%	0.43%	-0.42%	-0.04%	0.01%	-0.68%	0.58%	0.02%	0.41%
Net Income (Continuing)	-29.62M	-112.39M	-64.34M	-91.3M	-94.94M	-94.31M	-158.16M	-67.21M	-66.07M	-39.14M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.29	-2.80	-1.36	-1.62	-1.47	-1.05	-1.52	-0.42	-0.30	-0.17
EPS Growth %	-6.59%	-1.17%	0.51%	-0.19%	0.09%	0.29%	-0.45%	0.72%	0.29%	0.43%
EPS (Basic)	-1.29	-2.80	-1.36	-1.62	-1.47	-1.05	-1.52	-0.42	-0.30	-0.17
Diluted Shares Outstanding	22.89M	40.12M	47.44M	56.22M	64.48M	89.58M	104.21M	158.69M	219.33M	235.23M
Basic Shares Outstanding	22.89M	40.12M	47.44M	56.22M	64.48M	89.58M	104.21M	158.69M	219.33M	235.23M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	112.23M	203.99M	149.87M	177.72M	252.38M	195.24M	133.65M	153.6M	246.11M	356.45M
Cash & Short-Term Investments	107M	200.82M	133.98M	168.09M	247.51M	186.48M	116.69M	123.91M	184.3M	250.1M
Cash Only	107M	74.6M	75.38M	78.77M	181.13M	91.03M	72.43M	96.14M	21.47M	64.93M
Short-Term Investments	0	126.22M	58.59M	89.32M	66.38M	95.45M	44.26M	27.77M	162.83M	185.17M
Accounts Receivable	0	0	10.8M	5.08M	750K	0	502K	7.73M	22.03M	57.7M
Days Sales Outstanding	-	-	93.82	711.94	51.84	-	18.15	54.12	64.61	63.13
Inventory	0	0	0	0	0	0	0	3.28M	12.45M	21.17M
Days Inventory Outstanding	-	-	-	-	-	-	-	290.97	255.33	152.86
Other Current Assets	0	3.17M	0	0	0	0	1	5.11M	8.41M	11.1M
Total Non-Current Assets+	4.71M	9.14M	8.03M	5.61M	7.41M	6.32M	16.26M	36.46M	51.47M	79.3M
Property, Plant & Equipment	4.71M	8.99M	8.03M	5.61M	7.41M	4.21M	15.11M	10.52M	6.6M	3.88M
Fixed Asset Turnover	5.10x	2.67x	5.23x	0.46x	0.71x	1.80x	0.67x	4.96x	18.86x	86.09x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	100K	0	0	0	0	2.11M	0	0	0	0
Other Non-Current Assets	-100K	148K	0	0	0	0	1.15M	25.95M	44.87M	75.43M
Total Assets+	116.95M	213.13M	157.9M	183.33M	259.78M	201.56M	149.91M	190.07M	297.58M	435.75M
Asset Turnover	0.21x	0.11x	0.27x	0.01x	0.02x	0.04x	0.07x	0.27x	0.42x	0.77x
Asset Growth %	0.03%	0.82%	-0.26%	0.16%	0.42%	-0.22%	-0.26%	0.27%	0.57%	0.46%
Total Current Liabilities+	7.72M	19.2M	17.87M	17.73M	22.22M	28.42M	52.82M	65.6M	50.39M	77.83M
Accounts Payable	2.78M	5.63M	3.93M	1.15M	2.19M	5.63M	4.28M	10.86M	11.14M	16M
Days Payables Outstanding	1.22K	1.59K	170.9	899.18	1.33K	14.16K	1.56K	962.72	228.46	115.52
Short-Term Debt	0	0	0	0	3.79M	6.28M	32.26M	26.71M	0	0
Deferred Revenue (Current)	0	0	0	1000K	1000K	1000K	0	1000K	1000K	1000K
Other Current Liabilities	2.58M	10.4M	10.71M	12.86M	4.64M	5.22M	1.24M	10.09M	15.04M	49.58M
Current Ratio	14.53x	10.62x	8.39x	10.02x	11.36x	6.87x	2.53x	2.34x	4.88x	4.58x
Quick Ratio	14.53x	10.62x	8.39x	10.02x	11.36x	6.87x	2.53x	2.29x	4.64x	4.31x
Cash Conversion Cycle	-	-	-	-	-	-	-	-617.64	91.48	100.48
Total Non-Current Liabilities+	322K	779K	720K	49.79M	50.91M	47.03M	14.47M	26.13M	80.37M	184.63M
Long-Term Debt	0	0	0	49.21M	48.83M	46.62M	0	0	49.82M	150.85M
Capital Lease Obligations	0	0	0	0	2.08M	413K	9.75M	5.86M	1.73M	1.02M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	322K	779K	720K	582K	0	0	4.73M	11.25M	20.18M	25.53M
Total Liabilities	8.04M	19.98M	18.59M	67.52M	73.13M	75.45M	67.3M	91.74M	130.76M	262.46M
Total Debt+	0	0	0	49.21M	57.31M	55.44M	45.5M	36.46M	55.98M	153.44M
Net Debt	-107M	-74.6M	-75.38M	-29.56M	-123.83M	-35.6M	-26.92M	-59.68M	34.51M	88.51M
Debt / Equity	-	-	-	0.42x	0.31x	0.44x	0.55x	0.37x	0.34x	0.89x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-25.73x	-15.94x	-17.80x	-34.28x	-12.57x	-7.13x	-1.39x
Total Equity+	108.9M	193.15M	139.31M	115.81M	186.66M	126.11M	82.62M	98.33M	166.82M	173.29M
Equity Growth %	0.79%	0.77%	-0.28%	-0.17%	0.61%	-0.32%	-0.34%	0.19%	0.7%	0.04%
Book Value per Share	4.76	4.81	2.94	2.06	2.89	1.41	0.79	0.62	0.76	0.74
Total Shareholders' Equity	108.9M	193.15M	139.31M	115.81M	186.66M	126.11M	82.62M	98.33M	166.82M	173.29M
Common Stock	3K	5K	5K	6K	9K	9K	13K	20K	23K	24K
Retained Earnings	-101.49M	-213.88M	-278.21M	-365.51M	-460.45M	-554.76M	-712.93M	-780.14M	-846.2M	-885.34M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-3.81M	-71K	-47K	-38K	20K	-4K	-6K	-54K	224K	57K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-71.84M	-92.53M	-65.19M	-70.27M	-76.48M	-81.44M	-152.55M	-70.04M	-89.72M	-44.81M
Operating CF Margin %	-2.99%	-3.85%	-1.55%	-26.96%	-14.48%	-10.76%	-15.11%	-1.34%	-0.72%	-0.13%
Operating CF Growth %	-6.36%	-0.29%	0.3%	-0.08%	-0.09%	-0.06%	-0.87%	0.54%	-0.28%	0.5%
Net Income	-29.62M	-112.39M	-64.34M	-91.3M	-94.94M	-94.31M	-158.16M	-67.21M	-66.07M	-39.14M
Depreciation & Amortization	829K	1.29M	2.64M	2.68M	2.5M	1.82M	1.44M	1.14M	1.29M	2.06M
Stock-Based Compensation	2.63M	5.32M	9.59M	9.23M	9.94M	10.58M	12.04M	10.75M	13.53M	37.38M
Deferred Taxes	65K	-86K	11K	-1.02M	-262K	315K	-190K	0	0	0
Other Non-Cash Items	458K	540K	567K	792K	3.3M	3.37M	4.25M	4.84M	4.91M	4.05M
Working Capital Changes	-46.2M	12.79M	-13.66M	9.35M	2.98M	-3.21M	-11.92M	-19.57M	-43.39M	-49.17M
Change in Receivables	2.58M	0	-10.8M	10.71M	85K	750K	-502K	-7.23M	-14.3M	-35.67M
Change in Inventory	-2.08M	0	-1.9M	1.88M	-3.41M	-750K	-10.37M	-28.35M	-21.14M	-41.7M
Change in Payables	-371K	2.15M	-1.03M	-2.73M	39K	3.44M	-1.35M	6.58M	279K	4.86M
Cash from Investing+	-3.45M	-131.08M	65.29M	-29.89M	23.37M	-31.44M	50.95M	18.41M	-131.25M	-18.32M
Capital Expenditures	-3.45M	-4.87M	-2.35M	-311K	-325K	-324K	-1.87M	-55K	-344K	-1.01M
CapEx % of Revenue	0.14%	0.2%	0.06%	0.12%	0.06%	0.04%	0.18%	0%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-126.21M	67.64M	-29.58M	23.7M	-31.44M	52.81M	1.8M	0	0
Cash from Financing+	75.01M	191.2M	685K	103.55M	155.48M	22.78M	83M	75.34M	146.29M	106.59M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	689K	631K	685K	491K	574K	1.85M	1.3M	9.78M	4.67M	-1M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-75.29M	-97.4M	-67.55M	-70.58M	-76.81M	-81.76M	-154.42M	-70.1M	-90.06M	-45.82M
FCF Margin %	-3.13%	-4.05%	-1.61%	-27.08%	-14.54%	-10.8%	-15.29%	-1.34%	-0.72%	-0.14%
FCF Growth %	-7.52%	-0.29%	0.31%	-0.05%	-0.09%	-0.06%	-0.89%	0.55%	-0.28%	0.49%
FCF per Share	-3.29	-2.43	-1.42	-1.26	-1.19	-0.91	-1.48	-0.44	-0.41	-0.19
FCF Conversion (FCF/Net Income)	2.43x	0.82x	1.01x	0.77x	0.81x	0.86x	0.96x	1.04x	1.36x	1.14x
Interest Paid	0	0	0	0	4.92M	4.2M	3.47M	2.9M	4.24M	11.41M
Taxes Paid	69K	0	3K	4K	2K	1K	4K	6K	51K	266K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-34.93%	-74.42%	-38.7%	-71.57%	-62.78%	-60.31%	-151.55%	-74.28%	-49.83%	-23.01%
Return on Invested Capital (ROIC)	-1161.93%	-140.59%	-53.52%	-90.84%	-91.83%	-88.8%	-158.35%	-101.37%	-39.55%	-9.05%
Gross Margin	96.55%	94.61%	80%	82.13%	88.64%	98.08%	90.1%	92.11%	85.7%	84.85%
Net Margin	-123.29%	-467.77%	-153.19%	-3502.03%	-1797.77%	-1245.71%	-1566.46%	-128.85%	-53.08%	-11.73%
Debt / Equity	-	-	-	0.42x	0.31x	0.44x	0.55x	0.37x	0.34x	0.89x
Interest Coverage	-	-	-	-25.73x	-15.94x	-17.80x	-34.28x	-12.57x	-7.13x	-1.39x
FCF Conversion	2.43x	0.82x	1.01x	0.77x	0.81x	0.86x	0.96x	1.04x	1.36x	1.14x
Revenue Growth	-24.02%	0%	74.81%	-93.79%	102.57%	43.36%	33.36%	416.57%	138.61%	168.06%

Revenue by Segment

	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	300K	1.4M	-	15.6M	82.53M	319.2M
Product Growth	-	-	-	366.67%	-	-	429.01%	286.78%
Product, IBSRELA	-	-	-	-	-	-	80.06M	158.29M
Product, IBSRELA Growth	-	-	-	-	-	-	-	97.70%
License	-	2.32M	-	706K	5.01M	35.03M	35.81M	78K
License Growth	-	-	-	-	610.06%	598.80%	2.22%	-99.78%
Collaborative Development	-	-	-	-	4.18M	-	-	-
Collaborative Development Growth	-	-	-	-	-	-	-	-
Other Product Or Services Revenue	-	287K	322K	-	-	-	-	-
Other Product Or Services Revenue Growth	-	-	12.20%	-	-	-	-	-

Revenue by Geography

	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	-	-	-	-	15.6M	83.28M	319.2M
UNITED STATES Growth	-	-	-	-	-	-	433.82%	283.30%
North America	-	2.32M	-	806K	-	-	59K	14.34M
North America Growth	-	-	-	-	-	-	-	24206.78%
Asia Pacific	42M	287K	5.28M	6.76M	10.08M	36.53M	41.12M	78K
Asia Pacific Growth	-	-99.32%	1740.07%	28.10%	49.06%	262.23%	12.58%	-99.81%
CANADA	-	-	-	-	13K	31K	-	-
CANADA Growth	-	-	-	-	-	138.46%	-	-

Frequently Asked Questions

Growth & Financials

Ardelyx, Inc. (ARDX) reported $398.2M in revenue for fiscal year 2024. This represents a 7261% increase from $5.4M in 2012.

Ardelyx, Inc. (ARDX) grew revenue by 168.1% over the past year. This is strong growth.

Ardelyx, Inc. (ARDX) reported a net loss of $56.5M for fiscal year 2024.

Dividend & Returns

Ardelyx, Inc. (ARDX) has a return on equity (ROE) of -23.0%. Negative ROE indicates the company is unprofitable.

Ardelyx, Inc. (ARDX) had negative free cash flow of $55.3M in fiscal year 2024, likely due to heavy capital investments.